PHARMACOECONOMIC ANALYSIS OF DOCETAXEL IN THE ADJUVANT THERAPY OF BREAST CANCER
Abstract
Based on a clinical study BCIRG 001 (Martin M., Mackey J., Pienkowski T.) and as an outcome of Markov simulation it was determined that the use of 6DAC for adjuvant therapy in 10 year horizon of research allows to increase the disease-free survival by 6,09%, and overall survival by 5,88% comparing to 6FAC. Use of 6DAC instead of 6FAC allows to reduce the number of patients with local relapse, regional relapse and metastasis insignificantly as well. In the result of direct costs analysis it was determined that for 10-years horizon cost rate for the treatment of one patient with breast cancer will be 1 198 300 RUB for 6DAC and 1 371 184 RUB for 6FAC. Direct and indirect costs rate of the breast cancer treatment were 1 683 844 RUB and 1 973 043RUB for the 6DAC and 6FAC schemes respectively. It was determined that the scheme of adjuvant therapy that includes Docetaxel besides of addition efficiency, allows to reduce the cost rate to 289 199 RUB in 10 years.
About the Authors
R. I. YagudinaRussian Federation
Laboratory of pharmacoeconomic researches,
I. Yu. Zinchuk
Russian Federation
Laboratory of pharmacoeconomic researches,
References
1. Довгалюк А.З., Пазухова И.А. Рак молочной железы. СПб. 2001; С. 186.
2. Иванов В.Г., Семиглазов В.Ф., Семиглазов В.В., Криворотько П.В., Палтуев Р.М., Малодушева А.А., Зернов К.Ю., Жильцова Е.К., Донских Р.В. Таргетная (целевая) терапия РМЖ. Миф или реальность. Русcкий медицинский журнал. 2007; 15 (14): 1118-1123.
3. Злокачественные новообразования в России в 2010 году (заболеваемость и смертность) / Ассоц. онкологов России, ФБГУ Моск. науч.-исслед. онколог. ин-т им. П.А. Герцена. Под ред. В.И. Чиссова, В.В. Старинского, Г.В. Петровой. М. 2012; 260 с.
4. Новое поколение противораковых препаратов. Русский Медицинский журнал. 2007; 15 (14): 1115-1118.
5. Сергеева Н.С., Маршутина Н.В. Серологические опухолевые маркеры. В кн.: Онкология. Клинические рекомендации (2-е изд. испр. и доп.). М. 2009; 83-134.
6. Послание президента РФ Федеральному Собранию «Российская газета». 2007; №4272.
7. Martin M., Mackey J., Pienkowski T. Ten-year follow-up analysis of the BCIRG 001 trial confirms superior DFS and OS benefit of adjuvant TAC (docetaxel, doxorubicin, cyclophosphamide) over FAC (fluorouracil, doxorubicin, cyclophosphamide) in women with operable node-positive breast cancer. Cancer Research: December 15, 2010; 70(24). Supplement 2 DOI: 10.1158/0008-5472.SABCS10-S4-3 .
8. National Institute for Health and Clinical Excellence. http://www.nice.org.uk (12 November 2007, date last accessed).
Review
For citations:
Yagudina R.I., Zinchuk I.Yu. PHARMACOECONOMIC ANALYSIS OF DOCETAXEL IN THE ADJUVANT THERAPY OF BREAST CANCER. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2013;6(3):31-35.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 